PubHawk
N Engl J Med August 2023 PMID 37272516

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

Ingo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, Mehdi Touat, Katherine B Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F Hottinger

Download social card

Mentions

493
Peak: 53 in Aug 2023
across 6 sources since Jun 2023

Extended reach

8,000,823
potential audience

Total likes

603

Video views

1,509

Mentions per month

Jun 2023 – Oct 2025

Where it's discussed

  • News262 articles
  • X / Twitter210 posts
  • Blogs14 articles
  • Facebook4 posts
  • YouTube2 videos
  • Bluesky1 posts

AI synopsis

What people are saying

Several discussions emphasize key findings from the article, such as the significant improvement in progression-free survival for patients taking vorasidenib compared to those on placebo (27.7 months vs. 11.1 months). Phrases like 'game changer' and references to the potential for new treatment paradigms indicate a strong emotional resonance and critical engagement with the topic, showcasing how the publication may alter future treatment approaches.

AgreementStrong agreement

Most discussions strongly agree with the publication's findings, highlighting the effectiveness of vorasidenib in treating mutant gliomas.

InterestHigh interest

There is a high level of interest in the results presented, as many users express excitement about new treatment options.

EngagementHigh engagement

Many participants engage deeply with the content, discussing trial details, outcomes, and personal experiences related to glioma.

ImpactHigh impact

Users strongly believe that the publication marks a significant step forward in glioma treatment, anticipating changes in clinical practice.

Abstract in brief

  • Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are aggressive brain tumors, and vorasidenib is a promising oral treatment that targets these mutations and showed preliminary effectiveness.
  • A randomized phase 3 trial involved 331 patients with untreated residual or recurrent gliomas, comparing vorasidenib to a placebo over 28-day cycles, focusing on progression-free survival as the main outcome.
  • Results indicated that patients taking vorasidenib had significantly longer progression-free survival (27.7 months) compared to those on placebo (11.1 months) and experienced better outcomes before needing further treatment, although adverse effects were more common in the vorasidenib group.
Read the full abstract

Top posts

Most liked on X and Bluesky
NEJM
@NEJM · X

This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/zZZq4bpVu8

Dec 16, 2023 · 99 likes · 23 shares · 936,085 followers View post →
Liz Salmi
@TheLizArmy · X

Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib trial moved me in an indescribable way. Having lived w/grade 2 glioma for 16 yrs, I'm waiting for this next breakthrough.

Nov 19, 2023 · 63 likes · 7 shares · 8,350 followers View post →
Hope4Patients
@Dave46217976 · X

$NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negative narratives being spewed on iHub. Start at the 32 min mark: https://t.co/r5JFwVmATP

May 3, 2024 · 62 likes · 16 shares · 925 followers View post →
NEJM
@NEJM · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas https://t.co/kk794bUiqx

Aug 16, 2023 · 47 likes · 19 shares · 936,085 followers View post →
Toni Choueiri, MD
@DrChoueiri · X

Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glioma vs. placebo. mPFS, 27.7 vs. 11.1 months (HR: 0.39) @NEJM https://t.co/ZjGSfAF7Uf https://t.co/V0LiWj7UbF

Dec 30, 2023 · 42 likes · 11 shares · 42,866 followers View post →
下田健太郎/脳外科医
@shimoken_ns · X

成人脳腫瘍に光明の光が。 ヴォラシデニブがグリオーマグレード2に対して、無増悪生存期間を16ヵ月延長。成人脳腫瘍(グリオーマ:神経膠腫)はテモゾロミド以来、約20年間、画期的な治療薬が生み出されていない。日本でもこの薬を早く使えるようになることに期待したい。 https://t.co/TXuEhVvYba

Sep 27, 2023 · 31 likes · 1 share · 1,639 followers View post →

All mentions

Keiナカイ3.9
@keinakai2010 · X

これかぁ　 日本セルヴィエ株式会社「ボラニゴ®錠 」 効くの？ IDH変異は免疫染色でいいの？ https://t.co/dK0f5lR2RV

Oct 15, 2025 · 1,102 followers View post →
Brain Tumor News
@braintumor · X

Blockbuster relative citation ratio on IDH mutant tumors. https://t.co/CDG7tel3pR

Dec 26, 2024 · 1,393 followers View post →
عمار الخميسي . amar alkhamesi
@amar_uk1 · X

عقار جديد يقدم خيارًا لعلاج سرطان الدماغ. فوراسيدينيب vorasidenib عن طريق الفم (40 ملغ مرة واحدة يومياً). https://t.co/w8cuQFZhhf لم تكن هناك حبة دواء ناجح موجه للطفرة العلاجية معتمدة لسرطان الدماغ (الأورام الدبقية والأورام النجمية من الدرجة الثانية) التي تطيل فترة البقاء على

Sep 14, 2024 · 4 likes · 4,035 followers View post →
Andrew Caravello, DO
@andrewcaravello · X

RT @d_stock07734: Servier's Voranigo targets IDH1 and IDH2 mutated genes. https://t.co/2dVeVCQdpk https://t.co/jYzMnMJNF8 https://t.co/O…

Aug 20, 2024 · 1 share · 1,262 followers View post →
d_stock
@d_stock07734 · X

Servier's Voranigo targets IDH1 and IDH2 mutated genes. https://t.co/2dVeVCQdpk https://t.co/jYzMnMJNF8 https://t.co/OC54oukANA https://t.co/kn43E1h1uI

Aug 20, 2024 · 7 likes · 1 share · 583 followers View post →
Matthew Bower
@MBowerMD · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | New England Journal of Medicine https://t.co/e5RgFJlT2U

Aug 12, 2024 · 2 likes · 483 followers View post →
somekita@特発性血小板減少症＠EBIちゃん号
@mazuisake · X

RT @Matsuda_PhDPhD: Vorasidenibの構造はこんな感じ。研究用途であれば試薬メーカーから購入可能 https://t.co/kw0tBAu12X 元ツイに関連する試験結果はこちらのNEJM誌でも確認できます。OAです https://t.co/Wll7…

Aug 8, 2024 · 2 shares · 820 followers View post →
花鳥風月
@kachofugetsujp · X

RT @Matsuda_PhDPhD: Vorasidenibの構造はこんな感じ。研究用途であれば試薬メーカーから購入可能 https://t.co/kw0tBAu12X 元ツイに関連する試験結果はこちらのNEJM誌でも確認できます。OAです https://t.co/Wll7…

Aug 8, 2024 · 2 shares · 1,622 followers View post →
松田豊-抗体薬物複合体のケミスト-
@Matsuda_PhDPhD · X

Vorasidenibの構造はこんな感じ。研究用途であれば試薬メーカーから購入可能 https://t.co/kw0tBAu12X 元ツイに関連する試験結果はこちらのNEJM誌でも確認できます。OAです https://t.co/Wll71bCcAG https://t.co/h8Lt6ixV6w https://t.co/jkOHn0vk7W

Aug 8, 2024 · 5 likes · 2 shares · 5,194 followers View post →
Stanislav (Stas) Lazarev, MD
@StasLazarev · X

@Lojoga https://t.co/5CV2ls98vl

Aug 7, 2024 · 748 followers View post →
Shingo Kato@がんゲノム医
@shinkato_unagi · X

【脳】 VorasidenibはGrade2 IDH変異型神経膠腫において PFSおよび次の治療介入までの期間を延長した。 ボラシデニブ（vorasidenib）:変異型 IDH1 および IDH2 の経口阻害薬。 ふむ。 https://t.co/lPTpXwwJ06

Jun 18, 2024 · 5 likes · 1,087 followers View post →
HIGHSCORE
@JeffreyLake14 · X

RT @albtur_mnymkrs: May 2024 Neurology Recall: Topics in Neuro-Oncology Dr. Linda Liau on the study of vaccine-based therapy for GBM @ min…

May 4, 2024 · 4 shares · 529 followers View post →
Lisa
@LisainNJUSA · X

RT @sharpie510: #DCVax-L increased mOS not only in newly diagnosed #GBM but also recurrent #GBM. $NWBO has given us the first promising the…

May 3, 2024 · 1 share · 7,428 followers View post →
Mel Iiones
@al_bedone · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 140 followers View post →
Lisa
@LisainNJUSA · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 7,428 followers View post →
John Lane
@johnlane45 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 808 followers View post →
Silver Suntan
@Silver_Suntan · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 893 followers View post →
rj
@sharpie510 · X

#DCVax-L increased mOS not only in newly diagnosed #GBM but also recurrent #GBM. $NWBO has given us the first promising therapy in DECADES for #Glioblastoma!

May 3, 2024 · 15 likes · 1 share · 705 followers View post →
autologous assassin
@flaskworks · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 1,381 followers View post →
alphavestcapital.com
@alphavestcap · X

https://t.co/cVmdReiOIm $nwbo @alphavestcap

May 3, 2024 · 3 likes · 1,941 followers View post →
SchlangDaddy - Licensed to ILL
@SchlangDaddy · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 752 followers View post →
Margaret Monson
@MonsonVO · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 1,369 followers View post →
0wlet5
@0wlet5 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 655 followers View post →
StonkMaster
@StonkMasterJ · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 685 followers View post →
rj
@sharpie510 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 705 followers View post →
TiltMyBrain
@TiltMyBrain · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 837 followers View post →
Josh Taylor
@JoshTay02205534 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 129 followers View post →
Lars Bo Hansen
@LarsBoHansen10 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 256 followers View post →
Hoffmann
@hoffmann6383 · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 2,905 followers View post →
Andrew Caravello, DO
@andrewcaravello · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 1,256 followers View post →
eastvillagetwt
@eastvillagetwt · X

RT @Dave46217976: $NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negati…

May 3, 2024 · 16 shares · 2,456 followers View post →
Hope4Patients
@Dave46217976 · X

$NWBO #DCVAX Wow! Lots of really interesting info in this new video discussing #DCVAX-L. Dr L crushes a lot of the negative narratives being spewed on iHub. Start at the 32 min mark: https://t.co/r5JFwVmATP

May 3, 2024 · 62 likes · 16 shares · 925 followers View post →
Mionaer
@Mionaer1 · X

RT @albtur_mnymkrs: May 2024 Neurology Recall: Topics in Neuro-Oncology Dr. Linda Liau on the study of vaccine-based therapy for GBM @ min…

May 3, 2024 · 4 shares · 1,197 followers View post →
Kenneth
@Kenneth83risom · X

RT @albtur_mnymkrs: May 2024 Neurology Recall: Topics in Neuro-Oncology Dr. Linda Liau on the study of vaccine-based therapy for GBM @ min…

May 3, 2024 · 4 shares · 399 followers View post →
Peter Davis
@peter_brit · X

RT @albtur_mnymkrs: May 2024 Neurology Recall: Topics in Neuro-Oncology Dr. Linda Liau on the study of vaccine-based therapy for GBM @ min…

May 3, 2024 · 4 shares · 1,408 followers View post →
Ida Bogac
@albtur_mnymkrs · X

May 2024 Neurology Recall: Topics in Neuro-Oncology Dr. Linda Liau on the study of vaccine-based therapy for GBM @ min 00:32. $nwbo #dcvax https://t.co/yvdsBq0gvx

May 3, 2024 · 26 likes · 4 shares · 713 followers View post →
XEN MEANS X1 BLOCKCHAIN
@ILOVEYOUCRYPTO · X

RT @web8xen: 【Xenobots Journal Club】

Apr 21, 2024 · 7 shares · 1,403 followers View post →
BIG DADDY
@JituNandaniya · X

RT @web8xen: 【Xenobots Journal Club】

Apr 14, 2024 · 7 shares · 579 followers View post →
❤️memecoin
@VinhVinhnhat3 · X

RT @web8xen: 【Xenobots Journal Club】

Apr 13, 2024 · 7 shares · 811 followers View post →
SANJAYKUMAR SARODE
@sarodesanju9708 · X

RT @web8xen: 【Xenobots Journal Club】

Apr 13, 2024 · 7 shares · 167 followers View post →
XEN MEANS X1 BLOCKCHAIN
@ILOVEYOUCRYPTO · X

RT @web8xen: 【Xenobots Journal Club】

Apr 13, 2024 · 7 shares · 1,403 followers View post →
Adkins Hsiew
@AdkinsHsie87386 · X

RT @web8xen: 【Xenobots Journal Club】

Apr 13, 2024 · 7 shares · 229 followers View post →
ⓧ Tessy
@tessy_btc · X

RT @web8xen: 【Xenobots Journal Club】

Apr 13, 2024 · 7 shares · 3,685 followers View post →
ⓧ web8
@web8xen · X

【Xenobots Journal Club】

Apr 13, 2024 · 15 likes · 7 shares · 1,407 followers View post →
bbddpp
@bbddpp · X

RT @daniel_corcos: @wargonm Je demande à Servier ses résultats sur la survie dans son essai clinique, curieusement absents après un suivi d…

Apr 1, 2024 · 1 share · 3,126 followers View post →
mmhll
@MmhlLaurent · X

RT @daniel_corcos: @wargonm Je demande à Servier ses résultats sur la survie dans son essai clinique, curieusement absents après un suivi d…

Apr 1, 2024 · 1 share · 272 followers View post →
Daniel Corcos
@daniel_corcos · X

@wargonm Je demande à Servier ses résultats sur la survie dans son essai clinique, curieusement absents après un suivi de 28 mois ! https://t.co/jdT6g8xUt4

Apr 1, 2024 · 2 likes · 1 share · 6,776 followers View post →
Rolando Lovaton M.D.
@ROLANDO12612880 · X

El fármaco Vorasidenib, inhibidor de la enzima IDH mutante, prolonga la sobrevida de los pacientes con glioma grado II , IDH mutante, constituyendo un hito en el manejo de esta enfermedad. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/bd0Im6PMZr

Mar 2, 2024 · 2 likes · 31 followers View post →
Shearwood McClelland III, M.D.
@TheDrWood · X

RT @Timothee_MD: Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023 - setting =…

Jan 24, 2024 · 10 shares · 1,090 followers View post →
WANG Xingfu
@wangxfu · X

RT @EANOassociation:

Jan 16, 2024 · 9 shares · 994 followers View post →
Sally Rees
@sallyannehume · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 47 followers View post →
Junge Neuropathologen
@JungeNPath · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 184 followers View post →
Tessa Jowell Brain Cancer Mission
@TJBCMission · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 729 followers View post →
Andres F. Cardona
@AndresFCardonaZ · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 8,835 followers View post →
Camilla Satragno
@CamiSatragno · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 118 followers View post →
Angelo Dipasquale
@AngeloDipa_ · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 1,625 followers View post →
Kate Bowen
@kateandbowen · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 142 followers View post →
Jan-Michael Werner
@Jan_M_Werner · X

RT @EANOassociation:

Jan 15, 2024 · 9 shares · 583 followers View post →
EANO
@EANOassociation · X

Jan 15, 2024 · 15 likes · 9 shares · 4,278 followers View post →
Dr Celestino Gutiérrez González MD
@CelestinoGutirr · X

RT @NEJM: 2. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/BMmQDhsf…

Jan 7, 2024 · 3 shares · 11,308 followers View post →
Dr Ramdas Pananthattil
@PananthattilR · X

RT @NEJM: 3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.…

Jan 6, 2024 · 5 shares · 794 followers View post →
Dr Ramdas Pananthattil
@PananthattilR · X

RT @NEJM: 2. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/BMmQDhsf…

Jan 6, 2024 · 3 shares · 794 followers View post →
Honoris Causa
@jmm45_ · X

RT @NEJM: 2. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/BMmQDhsf…

Jan 6, 2024 · 3 shares · 657 followers View post →
Chidambara .ML.
@chidambara09 · X

RT @NEJM: 2. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/BMmQDhsf…

Jan 6, 2024 · 3 shares · 11,711 followers View post →
NEJM
@NEJM · X

2. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/BMmQDhsfeG

Jan 6, 2024 · 16 likes · 3 shares · 936,085 followers View post →
Kyaw Zin Thein, MD
@kyawzinthein86 · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Jan 2, 2024 · 11 shares · 825 followers View post →
James Janopaul-Naylor
@jjnaylor02 · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Jan 1, 2024 · 11 shares · 343 followers View post →
Vivek Subbiah, MD
@VivekSubbiah · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/czhayApJoX

Dec 31, 2023 · 4 likes · 38,972 followers View post →
Anas Ghazi, MD, MPH
@Anas_AlGhazi · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 31, 2023 · 11 shares · 29 followers View post →
Gláucia Alves de Souza, MD
@glaucia_asc · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 55 followers View post →
Eric Thompson, Ph.D.
@AZBioMarkers · X

RT @NEJM: 3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.…

Dec 30, 2023 · 5 shares · 409 followers View post →
Petros Grivas
@PGrivasMDPhD · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 18,436 followers View post →
Xxx SeX porN
@EMFTumorKill · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 907 followers View post →
Sinkmaster
@sinkmaster · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 752 followers View post →
Anant Jawahar Raina
@AJRaina01 · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 530 followers View post →
Patricia Garrido
@PatriGarri14 · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 922 followers View post →
Angelo Dipasquale
@AngeloDipa_ · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 1,625 followers View post →
ONCO BRUNO
@brunolarvol · X

RT @DrChoueiri: Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glio…

Dec 30, 2023 · 11 shares · 7,286 followers View post →
Toni Choueiri, MD
@DrChoueiri · X

Paper 9: Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glioma vs. placebo. mPFS, 27.7 vs. 11.1 months (HR: 0.39) @NEJM https://t.co/ZjGSfAF7Uf https://t.co/V0LiWj7UbF

Dec 30, 2023 · 42 likes · 11 shares · 42,866 followers View post →
Juan C Degiovanni
@juandegiovanni · X

RT @NEJM: 3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.…

Dec 30, 2023 · 5 shares · 2,451 followers View post →
Habib Cissé
@Kissiland_man · X

RT @NEJM: 3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.…

Dec 30, 2023 · 5 shares · 893 followers View post →
Christian Florely Pérez González
@DraChristianFP1 · X

RT @NEJM: 3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.…

Dec 30, 2023 · 5 shares · 149 followers View post →
NEJM
@NEJM · X

3. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO) https://t.co/qypyIPmLsy #BrainTumor https://t.co/OBIkhpISCF

Dec 30, 2023 · 18 likes · 5 shares · 936,085 followers View post →
Neurologia Bellvitge
@NeurologiaHUB · X

Vorasidenib significantly improved outcomes in patients with grade 2 IDH-mutant #glioma. Also, myocarditis, myasthenia, myositis, and encephalopathy independently predict mortality in ICI-related AEs. ▶️https://t.co/u7FFjBJhf2 @NEJM ▶️https://t.co/9ceCIh3Z3l @TheLancetNeuro

Dec 27, 2023 · 2 likes · 656 followers View post →
Robin Lewis Jones
@RobinL_Jones · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 17, 2023 · 23 shares · 2,489 followers View post →
Asexual Doctor
@Choji_ES · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 17, 2023 · 23 shares · 257,394 followers View post →
Rafael Angel Villino
@AngelVillino · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 17, 2023 · 23 shares · 42 followers View post →
Payals
@jpayals · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 17, 2023 · 23 shares · 54 followers View post →
octavio
@dontavo66 · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 331 followers View post →
Mariángel Gil
@Magil2006 · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 1,306 followers View post →
Fundacion Camilo Salinas S⚡️
@CamiloSalinasOF · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 6,699 followers View post →
RadiOncBOTjp
@RadiOncBOTjp · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 643 followers View post →
Dra. Carmen Tineo
@carmilia16 · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 187 followers View post →
El Chepo Gwapo.BTC
@DrGwapoLeon · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 677 followers View post →
Sol
@ArualSogar · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 795 followers View post →
Santhosh Ambika
@RenoHemonc · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 4,033 followers View post →
Stella M Macin
@StellaMMacin · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 551 followers View post →
K15
@K15mark423 · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 49 followers View post →
Ellie Edlmann
@EdlmannE · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 579 followers View post →
Chidambara .ML.
@chidambara09 · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 11,711 followers View post →
George Kolostoumpis
@gkolost · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 2,086 followers View post →
Julio César
@DrJulioMatuteM · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 1,421 followers View post →
Habib Cissé
@Kissiland_man · X

RT @NEJM: This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIP…

Dec 16, 2023 · 23 shares · 893 followers View post →
NEJM
@NEJM · X

This week’s most cited articles: 1. Original Article: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/qypyIPmLsy #Oncology https://t.co/zZZq4bpVu8

Dec 16, 2023 · 99 likes · 23 shares · 936,085 followers View post →
Liz Salmi
@TheLizArmy · X

@Jk_Jeffery @BTSMchat This. (Free preview. DM me if you need full access.) https://t.co/D9qBXmL0vf

Nov 20, 2023 · 2 likes · 8,350 followers View post →
Mathew Krick Gómez
@MathewKrick · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 20, 2023 · 7 shares · 72 followers View post →
Edjah Nduom, MD (he/him)
@EKNduom · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 11,121 followers View post →
Matt Englander
@MattEnglander · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 854 followers View post →
Low Grade Glioma Registry
@gliomaregistry · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 1,766 followers View post →
InnoCiter (CB(
@InnoCiter · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 500 followers View post →
Dave deBronkart
@ePatientDave · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 35,713 followers View post →
Alireza Mansouri
@DrAMansouri · X

RT @TheLizArmy: Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib t…

Nov 19, 2023 · 7 shares · 2,646 followers View post →
Liz Salmi
@TheLizArmy · X

Low grade IDH mutant glioma is having a moment right now. Listening to Cloughesy et al share results from the vorasidenib trial moved me in an indescribable way. Having lived w/grade 2 glioma for 16 yrs, I'm waiting for this next breakthrough.

Nov 19, 2023 · 63 likes · 7 shares · 8,350 followers View post →
Low Grade Glioma Registry
@gliomaregistry · X

Got to meet up with @YaleSPH @ysphbiostat graduate #DanZhao senior statistician for #Indigo #glioma #RCT check out her work here https://t.co/RmaoDnPGwj

Nov 19, 2023 · 1 like · 1,766 followers View post →
Nikhil Vasudeva
@DrNikhilvasudev · X

RT @Timothee_MD: Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023 - setting =…

Oct 27, 2023 · 10 shares · 2,188 followers View post →
Kusek
@Kusycki · X

RT @GCessak: Wyniki bad. klinicznego

Oct 6, 2023 · 3 shares · 2,694 followers View post →
Ola
@majolajam · X

RT @GCessak: Wyniki bad. klinicznego

Oct 4, 2023 · 3 shares View post →
Berni
@BezMistrza · X

RT @GCessak: Wyniki bad. klinicznego

Oct 3, 2023 · 3 shares · 1,905 followers View post →
GCessak
@GCessak · X

Wyniki bad. klinicznego

Oct 3, 2023 · 3 likes · 3 shares · 5,481 followers View post →
Yoshiki Arakawa (荒川 芳輝)
@YoshikiArakawa · X

https://t.co/tivUoWDmX5

Sep 29, 2023 · 67 followers View post →
saunner_p
@saunner_ph · X

RT @shimoken_ns: 成人脳腫瘍に光明の光が。 ヴォラシデニブがグリオーマグレード2に対して、無増悪生存期間を16ヵ月延長。成人脳腫瘍(グリオーマ:神経膠腫)はテモゾロミド以来、約20年間、画期的な治療薬が生み出されていない。日本でもこの薬を早く使えるようになること…

Sep 28, 2023 · 1 share · 106 followers View post →
下田健太郎/脳外科医
@shimoken_ns · X

成人脳腫瘍に光明の光が。 ヴォラシデニブがグリオーマグレード2に対して、無増悪生存期間を16ヵ月延長。成人脳腫瘍(グリオーマ:神経膠腫)はテモゾロミド以来、約20年間、画期的な治療薬が生み出されていない。日本でもこの薬を早く使えるようになることに期待したい。 https://t.co/TXuEhVvYba

Sep 27, 2023 · 31 likes · 1 share · 1,639 followers View post →
Cadence
@Cadence__K692 · X

RT @JavierM18255365: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/hfEiuWPEas Se abren cada día nuevas expectat…

Sep 27, 2023 · 2 shares · 39 followers View post →
Dr Ramdas Pananthattil
@PananthattilR · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Sep 13, 2023 · 19 shares · 794 followers View post →
Helen
@Helen__M2781 · X

RT @borras_ricard: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/4PRJ3rWOKC

Sep 5, 2023 · 1 share · 25 followers View post →
Biomedical Research
@BiomedicalRese1 · X

#Vorasidenib in IDH1- or IDH2-Mutant Low-Grade #Glioma #NeurologyRF #Medical For more: https://t.co/uDOkY9Y6PA

Aug 30, 2023 · 144 followers View post →
Neurology Today
@NeurologyToday · X

Via @NEJM: Vorasidenib, a brain-penetrant inhibitor of mutant enzymes, significantly improved progression-free survival and delayed the time to the next intervention in patients with grade 2 isocitrate dehydrogenase-mutant #glioma: https://t.co/kpIAVqyGtQ #NeuroTwitter @AANMember https://t.co/N5v8abbClC

Aug 28, 2023 · 2 likes · 64,869 followers View post →
2 Minute Medicine®
@2minmed · X

RT @2minmed: #VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #StudyGraphics #glioma https://t.co/6hGlb2E13G https://…

Aug 26, 2023 · 1 share · 5,408 followers View post →
2 Minute Medicine®
@2minmed · X

#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #StudyGraphics #glioma https://t.co/6hGlb2E13G https://t.co/ni35sll2vC

Aug 25, 2023 · 1 share · 5,408 followers View post →
Cancer_Evolve
@cancer_evolve · X

BRAIN: a small molecule IDH1/2 inhibitor (vorasidenib) improved PFS for patients with IDH1/2-mutant low grade glioma in a phase 3 RCT (PFS versus placebo 28 versus 11 months). https://t.co/iN964ENeVi

Aug 25, 2023 · 370 followers View post →
2 Minute Medicine®
@2minmed · X

RT @2minmed: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ChronicDisease #Oncology https://t.co/mg7DpXL3Ox https://t.co/3FQGeg6YFD

Aug 22, 2023 · 1 share · 5,408 followers View post →
NEJM
@NEJM · X

In NEJM, Mellinghoff et al. describe the results of the INDIGO trial, a phase 3 trial involving patients with residual or recurrent grade 2 glioma who had received no previous treatment other than surgery. Full trial results: https://t.co/qypyIPmLsy 4/15

Aug 22, 2023 · 1 share · 936,085 followers View post →
Chidambara .ML.
@chidambara09 · X

RT @2minmed: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ChronicDisease #Oncology https://t.co/mg7DpXL3Ox https://t.co/3FQGeg6YFD

Aug 21, 2023 · 1 share · 11,711 followers View post →
Dr John Manzella
@DrJohnRManzella · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma - 2 Minute Medicine https://t.co/sAwFoYOBQl

Aug 21, 2023 · 2,018 followers View post →
2 Minute Medicine®
@2minmed · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ChronicDisease #Oncology https://t.co/mg7DpXL3Ox https://t.co/3FQGeg6YFD

Aug 21, 2023 · 1 share · 5,408 followers View post →
ARPIT MATHUR
@mathurarpit21 · X

https://t.co/fIXkcTr7wy

Aug 20, 2023 · 232 followers View post →
Ricard Borrás Ferreres
@borras_ricard · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/4PRJ3rWOKC

Aug 19, 2023 · 2 likes · 1 share · 111 followers View post →
Princess Margaret Cancer Centre
@pmcancercentre · X

Congratulations to Dr. Warren Mason, a co-author in a trial of the drug Vorasidenib that found it helped patients with IDH Mutant Low Grade Gliomas – a type of brain tumour. Study published in @NEJM. Read here → https://t.co/glA0mv3mZE

Aug 18, 2023 · 14 likes · 7,909 followers View post →
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/s4AphXpmL8

Aug 18, 2023 · 4 likes · 18,490 followers View post →
Giuseppe Ingravallo
@GiuseppeIngrav2 · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/tN0Jot0s7H

Aug 18, 2023 · 1 like · 644 followers View post →
Ivo Parpinelli
@parpinellivo · X

RT @RobertoBurioni: Articolo completo https://t.co/z629qA8ZLL

Aug 18, 2023 · 4 shares · 848 followers View post →
Waggoner Lab
@LabWaggoner · X

In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention @NEJM https://t.co/2lwFvQlXPm

Aug 17, 2023 · 11,452 followers View post →
Capu B
@CapuBaldini · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 500 followers View post →
Alexandr Poprach
@APoprach · X

RT @roelverhaak: The INDIGO trial (https://t.co/zatdDqbI1C) shows that vorasidenib treatment delays tumor progression for patients with IDH…

Aug 17, 2023 · 20 shares · 142 followers View post →
Marcus Alexander, MD, PhD
@mqdicer · X

RT @roelverhaak: The INDIGO trial (https://t.co/zatdDqbI1C) shows that vorasidenib treatment delays tumor progression for patients with IDH…

Aug 17, 2023 · 20 shares · 1,352 followers View post →
Hattorianzo
@Hattoriando · X

RT @RobertoBurioni: Articolo completo https://t.co/z629qA8ZLL

Aug 17, 2023 · 4 shares · 1,037 followers View post →
tanedalof
@tanedalof · X

RT @roelverhaak: The INDIGO trial (https://t.co/zatdDqbI1C) shows that vorasidenib treatment delays tumor progression for patients with IDH…

Aug 17, 2023 · 20 shares · 32 followers View post →
Mariángel Gil
@Magil2006 · X

RT @irodriguezpenin: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/z5szxBtWSu

Aug 17, 2023 · 1 share · 1,306 followers View post →
Inma
@inmasve · X

RT @roelverhaak: The INDIGO trial (https://t.co/zatdDqbI1C) shows that vorasidenib treatment delays tumor progression for patients with IDH…

Aug 17, 2023 · 20 shares · 105 followers View post →
Actualfarma
@Actualfarma1 · X

RT @gedefo_sefh: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Median PFS 27.7 m vs 11.1 m; HR 0.39; 95% CI (0.27 - 0.56); P<0.001 h…

Aug 17, 2023 · 1 share · 554 followers View post →
Bo Sun
@neuro_bo · X

RT @roelverhaak: The INDIGO trial (https://t.co/zatdDqbI1C) shows that vorasidenib treatment delays tumor progression for patients with IDH…

Aug 17, 2023 · 20 shares · 959 followers View post →
Isaura R. Penin
@irodriguezpenin · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/z5szxBtWSu

Aug 17, 2023 · 1 like · 1 share · 623 followers View post →
Ikudayisi Ekiti Johnson Olawale
@IkudayisiJ · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 2,242 followers View post →
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE
@TomVargheseJr · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 25,839 followers View post →
ALASA PILLS
@AlasaPills · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 2,525 followers View post →
Ana H. ۞ andaluza que no pronuncia la S final
@otrattwitera · X

RT @JavierM18255365: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/hfEiuWPEas Se abren cada día nuevas expectat…

Aug 17, 2023 · 2 shares · 229 followers View post →
GEDEFO
@gedefo_sefh · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Median PFS 27.7 m vs 11.1 m; HR 0.39; 95% CI (0.27 - 0.56); P<0.001 https://t.co/1DIc7vv2T2

Aug 17, 2023 · 3 likes · 1 share · 5,442 followers View post →
Biomedical Research
@BiomedicalRese1 · X

#Vorasidenib in IDH1- or IDH2-Mutant Low-Grade #Glioma For more: https://t.co/uDOkY9Y6PA

Aug 17, 2023 · 144 followers View post →
Javier Márquez
@JavierM18255365 · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/hfEiuWPEas Se abren cada día nuevas expectativas para nuestros pacientes con tumores cerebrales tras la cirugía .

Aug 17, 2023 · 1 like · 2 shares · 692 followers View post →
Actualfarma
@Actualfarma1 · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 554 followers View post →
GENEINFO
@LMihajlovi · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 941 followers View post →
EANO
@EANOassociation · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 17, 2023 · 19 shares · 4,278 followers View post →
Dr. Shashank Joshi
@AskDrShashank · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 32,525 followers View post →
Prof. Lee Machado
@drleemachado · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/42nDANyhjj @MichaelNaidoo6 @Weekademia

Aug 16, 2023 · 1 like · 1,665 followers View post →
Ezeonufo Chukwunonso
@Ezeonufo · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 1,359 followers View post →
Stuart Smith
@SjsmithStuart · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 155 followers View post →
Patxi Queipo
@patxiqueipo · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 447 followers View post →
たぬぽん
@west_east_NA · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 478 followers View post →
شَـهـيِدْ
@ShaheedKhalid · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 281 followers View post →
freddieewbank
@freddieewbank1 · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 276 followers View post →
バン@内科医のジレンマ
@lostphysicianYB · X

RT @NEJM: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors w…

Aug 16, 2023 · 19 shares · 4,360 followers View post →
NEJM
@NEJM · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (INDIGO): https://t.co/qypyIPmdD0 Editorial: Headway against Brain Tumors with Molecular Targeting of IDH-Mutant Gliomas https://t.co/kk794bUiqx

Aug 16, 2023 · 47 likes · 19 shares · 936,085 followers View post →
Amira A
@Passionate2024 · X

RT @JoshuaBudhu: ICYMI: Positive data from the Vorasidenib trial - practice changing and represents a new therapy for glioma patients. Vor…

Aug 8, 2023 · 2 shares · 553 followers View post →
Melvin Parasram, DO, MS
@mel_para · X

RT @JoshuaBudhu: ICYMI: Positive data from the Vorasidenib trial - practice changing and represents a new therapy for glioma patients. Vor…

Aug 8, 2023 · 2 shares · 1,053 followers View post →
Joshua Budhu
@JoshuaBudhu · X

ICYMI: Positive data from the Vorasidenib trial - practice changing and represents a new therapy for glioma patients. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/eyxnufOkSM

Aug 8, 2023 · 9 likes · 2 shares · 3,601 followers View post →
Muhammad Awais Khan
@__AwaisKhan_ · X

RT @official_pans: August 8, 2023 at 1:00 PM At last a drug is here (vorasidenib) for low grade glioma that has been shown to significantl…

Aug 6, 2023 · 1 share · 1,166 followers View post →
Pakistan Academy of Neurological Surgery
@official_pans · X

August 8, 2023 at 1:00 PM At last a drug is here (vorasidenib) for low grade glioma that has been shown to significantly improve progression-free survival and delay of the time to the next intervention. Ref: Vorasidenib in IDH1- or IDH2-Mutant | Low-Grade Glioma https://t.co/SI9JEa6mO6

Aug 6, 2023 · 10 likes · 1 share · 1,914 followers View post →
Julio Pereira
@julio_neurosp · X

RT @julio_neurosp: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Ingo K Mellin…

Aug 5, 2023 · 5 shares · 3,223 followers View post →
Stacey L. Clardy
@staceylclardy.bsky.social · Bluesky

MedSky - Here is a link to the NEJM article: https://www.nejm.org/doi/full/10.1056/NEJMoa2304194?utm_source=twitter&utm_medium=organic

Jul 24, 2023 · 1 like View post →
Dr. Poetic
@Dr_Doc_ · X

https://t.co/azrzBzqkYY https://t.co/avJT4Oract

Jul 12, 2023 · 3,027 followers View post →
Neurocirurgia São Paulo
@neuro_oncologia · X

RT @julio_neurosp: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Ingo K Mellin…

Jul 6, 2023 · 5 shares · 1,715 followers View post →
Radiocirurgia
@radiocirurgia · X

RT @julio_neurosp: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Ingo K Mellin…

Jul 6, 2023 · 5 shares · 1,264 followers View post →
Tom
@youareinformed · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/WcdvawRPou

Jun 14, 2023 · 3,276 followers View post →
NP AGARWAL世界一フォローを目指しますAiming best in world.
@np_grwl · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 14, 2023 · 10 shares · 1,793 followers View post →
NP AGARWAL世界一フォローを目指しますAiming best in world.
@np_grwl · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 14, 2023 · 9 shares · 1,793 followers View post →
Brain tumor ULisboa
@braintumor_UL · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma https://t.co/Md5jEF9E80

Jun 14, 2023 · 1 like · 248 followers View post →
Sid Chopra
@skchopra007 · X

RT @ravboc: Patients with a certain type of brain tumor could soon be treated with an oral drug (Vorasidenib) instead of undergoing more to…

Jun 11, 2023 · 2 shares · 946 followers View post →
Asif Ashraf
@AroMasif · X

RT @ravboc: Patients with a certain type of brain tumor could soon be treated with an oral drug (Vorasidenib) instead of undergoing more to…

Jun 11, 2023 · 2 shares · 24 followers View post →
Ram Vishwakarma
@R_A_Vishwakarma · X

Patients with a certain type of brain tumor could soon be treated with an oral drug (Vorasidenib) instead of undergoing more toxic chemotherapy and radiation, which could change the treatment landscape - the drug from Servier awaiting approval. https://t.co/e3gDxPjv8u

Jun 10, 2023 · 7 likes · 2 shares · 898 followers View post →
MacArena
@MacArena_Salud · X

RT @FREELANCEROG: #glioma #vorasidenib #IDH1 #IDH2 #Mutant https://t.co/REltClUkPR https://t.co/mIDMFKECeT

Jun 7, 2023 · 2 shares · 514 followers View post →
Amadeo Wals
@AmadeoWals · X

RT @FREELANCEROG: #glioma #vorasidenib #IDH1 #IDH2 #Mutant https://t.co/REltClUkPR https://t.co/mIDMFKECeT

Jun 7, 2023 · 2 shares · 1,502 followers View post →
FROG
@FREELANCEROG · X

#glioma #vorasidenib #IDH1 #IDH2 #Mutant https://t.co/REltClUkPR https://t.co/mIDMFKECeT

Jun 7, 2023 · 2 shares · 1,168 followers View post →
serrgv
@serrgv · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 147 followers View post →
serrgv
@serrgv · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 147 followers View post →
Vince Beltran, Ph.D.
@levin_beltran · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 11,744 followers View post →
Dr Anthony Martin
@AMAinsight · X

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma | NEJM https://t.co/LhsmQAGalM

Jun 5, 2023 · 914 followers View post →
Serafina
@Serafina83837 · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 371 followers View post →
Nida Jung
@IMuly18Niders · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 37 followers View post →
K.Serrano, MD
@klintonserrano · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 403 followers View post →
Stephen Strange
@jaydeepdhokia · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 34 followers View post →
pbhardwaj
@pbh54 · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 163 followers View post →
Medical Xpress
@physorg_health · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 7,101 followers View post →
Phys.org
@physorg_com · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 1,024,257 followers View post →
Science X
@sciencex_com · X

RT @medical_xpress: Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.…

Jun 5, 2023 · 9 shares · 3,532 followers View post →
Medical Xpress
@medical_xpress · X

Clinical trial points to treatment advances for #glioma patients for first time in decades @danafarber @nejm https://t.co/aFqY7HFiHm https://t.co/8otrLlNEle

Jun 5, 2023 · 12 likes · 9 shares · 173,160 followers View post →
Klinger Neves
@Kli_Nev · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 3,844 followers View post →
Irlandia
@Irlandia · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 4,001 followers View post →
Phys.org
@physorg_com · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 1,024,257 followers View post →
Medical Xpress
@physorg_health · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 7,101 followers View post →
Science X
@sciencex_com · X

RT @medical_xpress: New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm http…

Jun 5, 2023 · 10 shares · 3,532 followers View post →
Medical Xpress
@medical_xpress · X

New drug delays progression of glioma, a deadly brain #cancer, during clinical trial @nejm https://t.co/aFqY7HFiHm https://t.co/or4O4PHYBt

Jun 5, 2023 · 16 likes · 10 shares · 173,160 followers View post →